As of 2026-07-04, the Relative Valuation of Neovacs SA (ALNEV.PA) is (363.19) EUR. This relative valuation is based on P/E multiples. With the latest stock price at 1.66 EUR, the upside of Neovacs SA based on Relative Valuation is -21978.7%.
The range of the Relative Valuation is (326.13) - (527.14) EUR.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 9.5x - 17.8x | 12.5x |
| Forward P/E multiples | 11.0x - 18.2x | 12.0x |
| Fair Price | (326.13) - (527.14) | (363.19) |
| Upside | -19746.2% - -31855.4% | -21978.7% |
| Date | P/E |
| 2026-06-29 | -0.05 |
| 2026-06-26 | -0.05 |
| 2026-06-23 | -0.06 |
| 2026-06-22 | -0.07 |
| 2026-06-18 | -0.07 |
| 2026-06-17 | -0.07 |
| 2026-06-16 | -0.07 |
| 2026-06-15 | -0.07 |
| 2026-06-12 | -0.07 |
| 2026-06-11 | -0.07 |
| 2026-06-10 | -0.07 |
| 2026-06-09 | -0.07 |
| 2026-06-08 | -0.07 |
| 2026-06-05 | -0.07 |
| 2026-06-04 | -0.07 |
| 2026-06-03 | -0.07 |
| 2026-06-02 | -0.13 |
| 2026-06-01 | -0.13 |
| 2026-05-29 | -0.07 |
| 2026-05-28 | -0.07 |
| 2026-05-27 | -0.07 |
| 2026-05-26 | -0.07 |
| 2026-05-25 | -0.07 |
| 2026-05-22 | -0.07 |
| 2026-05-21 | -0.13 |
| 2026-05-20 | -0.07 |
| 2026-05-19 | -0.07 |
| 2026-05-18 | -0.07 |
| 2026-05-15 | -0.07 |
| 2026-05-14 | -0.07 |
| 2026-05-13 | -0.07 |
| 2026-05-12 | -0.07 |
| 2026-05-11 | -0.07 |
| 2026-05-08 | -0.07 |
| 2026-05-07 | -0.07 |
| 2026-05-06 | -0.07 |
| 2026-05-05 | -0.07 |
| 2026-05-04 | -0.07 |
| 2026-04-30 | -0.07 |
| 2026-04-29 | -0.07 |
| 2026-04-28 | -0.07 |
| 2026-04-27 | -0.07 |
| 2026-04-24 | -0.13 |
| 2026-04-23 | -0.13 |
| 2026-04-22 | -0.13 |
| 2026-04-21 | -0.13 |
| 2026-04-20 | -0.07 |
| 2026-04-17 | -0.13 |
| 2026-04-16 | -0.13 |
| 2026-04-15 | -0.13 |